Trial Profile
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Rising Dose Study to Explore the Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of SB26 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs SB-26 (Primary)
- Indications Pancreatitis
- Focus Adverse reactions; First in man
- Sponsors Samsung Bioepis
- 22 Apr 2020 Status changed from recruiting to completed.
- 07 Jan 2020 Planned End Date changed from 26 Mar 2020 to 23 Apr 2020.
- 07 Jan 2020 Planned primary completion date changed from 26 Mar 2020 to 23 Apr 2020.